Merck enters supply agreement with U.S. government for molnupiravir
Category: #healthcare  By Mateen Dalal  Date: 2021-06-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck enters supply agreement with U.S. government for molnupiravir
  • The COVID-19 antiviral course will be supplied only after FDA provides a EUA.
  • Molnupiravir is currently in its phase 3 clinical trial.

Merck & Co. Inc. has reportedly entered a supply agreement with the U.S. government for molnupiravir, an oral antiviral drug for treating mild to moderate COVID-19. The American pharmaceutical giant would receive approximately USD 1.2 billion from the U.S government for supplying around 1.7 million courses.

According to reliable sources, Merck will supply these antiviral courses only after it receives a EUA from the U.S. Food & Drug Administration (FDA). Molnupiravir, which is co-developed with Ridgeback Biotherapeutics, is currently in its Phase 3 clinical trial called the MOVe-OUT study.

For those unaware, molnupiravir can potentially prevent the replications of multiple RNA viruses including SARS-CoV-1, MERS, and SARS-COV-2. The antiviral, at present, is in its phase 3 trial to evaluate its potential to reduce hospitalization as well as mortality rates.

Merck, meanwhile, has been making significant investments to upscale the production of molnupiravir and expects to produce around 10 million doses of the antiviral by the fourth quarter of 2021.

Rob Davis, President at Merck & Co., was quoted saying that the supply agreement with the U.S. government will help in providing easy access to molnupiravir which is yet to receive a EUA. He added that apart from the U.S. distribution deal, the company is also working towards making the drug available across the globe.

Merck claims to have signed various non-exclusive voluntary licensing agreements with esteemed manufacturers to enhance the accessibility of molnupiravir in low- and middle-income countries, after obtaining relevant authorization or approvals.

Apart from developing molnupiravir, Merck has also been contributing to the pandemic response by teaming up with Johnson & Johnson to boost the production capabilities of its COVID-19 vaccine.

Source credits –

https://www.businesswire.com/news/home/20210609005142/en/Merck-Announces-Supply-Agreement-with-U.S.-Government-for-Molnupiravir-an-Investigational-Oral-Antiviral-Candidate-for-Treatment-of-Mild-to-Moderate-COVID-19

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Airbus records 38% rise in deliveries; Lufthansa readjusts A350 orders
Airbus records 38% rise in deliveries; Lufthansa readjusts A350 orders
By Mateen Dalal

Shares of Airbus rose by 0.5% during Tuesday trading. Lufthansa’s reshuffling orders were a...

Reliance Foundation looking to import Johnson & Johnson’s COVID-19 jab
Reliance Foundation looking to import Johnson & Johnson’s COVID-19 jab
By Mateen Dalal

India’s largest non-profit organization is currently seeking government approval. Reliance...

CDK Global buys e-comm ‘car buying’ platform Roadster for USD 360 Mn
CDK Global buys e-comm ‘car buying’ platform Roadster for USD 360 Mn
By Mateen Dalal

U.S.-based integrated data and technology solutions provider CDK Global has reportedly acquired Road...